Baxter International Inc.

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 10:50:30 20/09/2024 pm IST 5-day change 1st Jan Change
38.44 USD -0.81% Intraday chart for Baxter International Inc. -3.06% -0.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
-Baxter International Inc. Appoints Jeffrey A. Craig to Its Board CI
Baxter International Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-05-2024 01:30 PM
Baxter International Inc. Announces Executive Changes CI
Waters Corporation Appoints Heather Knight to Board of Directors CI
JPMorgan Adjusts Price Target on Baxter International to $38 From $42 MT
Health Care Up on Sector Momentum -- Health Care Roundup DJ
Producer Prices Report Buoys Equities Ahead of Consumer Inflation Data MT
Producer Prices Report Buoys Equities Ahead of Consumer Inflation Data MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
US Equities Markets End Higher Tuesday as Producer Prices Rise Less Than Expected MT
Baxter to Sell Kidney Care Segment to Carlyle Group in $3.8 Billion Deal MT
Equities Rise Intraday After Producer Prices Report MT
Sector Update: Health Care Stocks Higher Tuesday Afternoon MT
Sector Update: Health Care MT
Top Midday Stories: Home Depot Lowers Full-Year Adjusted EPS Guidance; Starbucks Names Chipotle CEO as New Chief Executive MT
Carlyle to buy Baxter's kidney-care spinoff Vantive for $3.8 billion RE
Sector Update: Health Care Stocks Edge Higher Premarket Tuesday MT
Baxter International Sells Kidney Care Unit to Carlyle Group for $3.8 Billion MT
Baxter International to Sell Kidney Care Segment to Carlyle for $3.8 Billion MT
Carlyle Appoints Kieran Gallahue as Chairman of Vantive CI
Carlyle to buy Baxter's kidney-care spinoff Vantive for $3.8 billion RE
The Carlyle Group Inc. (NasdaqGS:CG) and Atmas Health entered into an equity purchase agreement to acquire Vantive Health LLC, Vantive Mexico LLC, Gambro Renal Products, Inc., RTS Worldwide Holdings Inc., Vantive Holding B.V. and Vantive Health GmbH from Baxter International Inc. for $3.8 billion. CI
JPMorgan Adjusts Price Target on Baxter International to $42 From $44 MT
Jefferies Adjusts Price Target on Baxter International to $42 From $43 MT
Wells Fargo Adjusts Price Target on Baxter International to $40 From $44 MT
Chart Baxter International Inc.
More charts
Logo Baxter International Inc.
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.
Employees
60,000
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
15
Last Close Price
38.76USD
Average target price
42.09USD
Spread / Average Target
+8.60%
Consensus
  1. Stock Market
  2. Equities
  3. BAX Stock
  4. News Baxter International Inc.
  5. Sector Update: Health Care Stocks Edge Higher Premarket Tuesday